Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.03 is 37% above its 3-year average of 0.02, near the high end of its 3-year range (-3.17–0.15).
As of the fiscal period ended Tuesday, June 30, 2026. 9.07% below its 12-month average of 0.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.03.
DEBT TO EQUITY RATIO
0.03
DEBT TO EQUITY RATIO AVG TTM
0.03
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-9.07%
CURRENT VS 3Y AVG
+24.36%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 711 covered companies
CURRENT VS SECTOR MEDIAN
-75.06%
vs the sector median at left
Contineum Therapeutics, Inc.
Market Cap
$471.20M
Debt to Equity Ratio
0.03
TTM Avg
0.03
3Y Avg
0.02
5Y Avg
N/A
Market Cap
$470.86M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$466.84M
Debt to Equity Ratio
0.79
TTM Avg
0.55
3Y Avg
0.40
5Y Avg
0.35
Market Cap
$475.60M
Debt to Equity Ratio
1.10
TTM Avg
1.63
3Y Avg
1.59
5Y Avg
1.34
Market Cap
$486.34M
Debt to Equity Ratio
0.03
TTM Avg
0.51
3Y Avg
2.10
5Y Avg
2.10
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | $471.20M | 0.03 | 0.03 | 0.02 | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $470.86M | 0.00 | 0.01 | 0.01 | 0.01 |
| Kamada Ltd. (KMDA)vs › | $469.63M | 0.04 | 0.04 | 0.06 | 0.07 |
| Sight Sciences, Inc. (SGHT)vs › | $466.84M | 0.79 | 0.55 | 0.40 | 0.35 |
| Cerus Corporation (CERS)vs › | $475.60M | 1.10 | 1.63 | 1.59 | 1.34 |
| Arvinas, Inc. (ARVN)vs › | $475.20M | 0.01 | 0.02 | 0.01 | 0.01 |
| NRC Health (NRC)vs › | $459.07M | 13.75 | 3.86 | 2.21 | 1.62 |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.34M | 0.03 | 0.51 | 2.10 | 2.10 |
| Evolus, Inc. (EOLS)vs › | $490.20M | N/A | 23.54 | 9.49 | 7.42 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $447.04M | 0.00 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.03
Current Ratio
37.17
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.03 |
| 2026-03-31 | 0.03 |
| 2025-12-31 | 0.03 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.03 |
| 2024-12-31 | 0.03 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | -2.55 |
| 2023-12-31 | -2.84 |
| 2023-09-30 | -3.17 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.15 |
